AMBISOME by Astellas is clinical pharmacology pharmacokinetics the assay used to measure amphotericin b in the serum after administration of am b isome does not distinguish amphotericin b that is complexed with the phospholipids of am b isome from amphotericin b that is uncomplexed. First approved in 1997.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AmBisome is a liposomal formulation of amphotericin B, a small-molecule antifungal agent approved in 1997 for treatment of serious fungal infections in immunocompromised patients. The liposomal delivery system reduces systemic toxicity while maintaining fungicidal activity against a broad spectrum of fungi. It works by binding to fungal cell membranes and disrupting cell integrity.
Product is in late-stage lifecycle with minimal Medicare claims (463 in 2023), indicating a mature, limited-use specialty injectable with small commercial team.
CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the serum after administration of Am B isome does not distinguish amphotericin B that is complexed with the phospholipids of Am B isome from amphotericin B that is uncomplexed. The pharmacokinetic profile of…
Worked on AMBISOME at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics
PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAmBisome roles are concentrated in specialty hospital/oncology channels with emphasis on maintaining market share in niche indications rather than growth. Career trajectory involves managing product maturity, competitive defense, and efficient cost structures in anticipation of generic competition.